Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sustained-release verapamil formulations for treating hypertension.

W H Frishman1, E J Lazar

  • 1Department of Medicine, Hospital of The Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York 10461.

Journal of Clinical Pharmacology
|May 1, 1992
PubMed
Summary

Verapamil, a key calcium-channel blocker for hypertension, now offers improved formulations for convenient once-daily dosing. These newer verapamil options provide sustained blood pressure control and better patient compliance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AIDS and the heart: Clinicopathologic assessment.

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology·2015
Same author

Process of care events in transplantation: effects on the cost of hospitalization.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2010
Same author

ACE inhibitors and the arterial wall. Introduction.

Postgraduate medicine·2009
Same author

Pathophysiology and medical management of systemic hypertension and pre-eclampsia in pregnancy.

Minerva medica·2006
Same author

Antiplatelet therapy: glycoprotein IIb/IIIa receptor antagonists.

Drugs of today (Barcelona, Spain : 1998)·2003
Same author

Alcohol as a cardioprotective agent.

Heart disease (Hagerstown, Md.)·2002

Area of Science:

  • Cardiovascular Pharmacology
  • Pharmacokinetics
  • Hypertension Management

Background:

  • Verapamil, a foundational calcium-channel blocker, is widely used for systemic hypertension.
  • Its short half-life necessitates frequent dosing, impacting patient adherence.
  • Advancements in drug delivery have led to improved verapamil formulations.

Purpose of the Study:

  • To review the evolution of verapamil formulations for hypertension treatment.
  • To highlight the benefits of newer sustained-release and pellet-filled capsule formulations.
  • To assess the impact on dosing frequency, efficacy, and patient convenience.

Main Methods:

  • Review of clinical data and pharmacokinetic studies on verapamil formulations.
  • Comparison of traditional verapamil dosing with sustained-release and new capsule formulations.

Related Experiment Videos

  • Analysis of factors influencing verapamil absorption and blood pressure control.

    • Main Results:

    • Sustained-release verapamil allows once-daily dosing up to 240 mg/d, with higher doses requiring twice-daily administration.
    • New pellet-filled capsule formulations (Verelan) offer controlled 24-hour blood pressure control with once-daily dosing, irrespective of dose.
    • These advanced formulations improve peak-to-trough plasma levels and allow administration without regard to food intake.

    Conclusions:

    • Newer verapamil formulations significantly enhance convenience and therapeutic outcomes for hypertension management.
    • Once-daily dosing and improved pharmacokinetic profiles of advanced verapamil formulations increase patient adherence.
    • Verapamil remains a vital therapeutic option, with formulation advancements optimizing its clinical utility.